Organisation paid for research Program year 2022 Source: CMS Open Payments

Avail Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$43,339

26 payments

Through program year 2022, Avail Clinical Research, LLC is reported as receiving $43,339 in research payments, across 26 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $5,500 2
2020 Research $24,292 17
2019 Research $13,547 7

Breakdown

Who paid Research payments · program years 2019–2022
  1. Gilead Sciences, Inc. $16,515 9 payments
  2. Vifor (International) Ltd. $15,372 10 payments
  3. Dr.Reddy's Laboratories,Inc. $5,500 2 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $3,558 1 payment
  5. Boehringer Ingelheim International GmbH $2,394 4 payments
Studies the money was for Research payments · program years 2019–2022
  1. Diamond Pat-Cr-302 $15,372 10 payments
  2. A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3) $5,500 2 payments
  3. Empagliflozin and heart failure (HFpEF) $3,558 1 payment
  4. STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis $3,059 1 payment
  5. STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) $2,468 1 payment
  6. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease $2,468 1 payment
  7. STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis $2,468 1 payment
  8. STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis $2,433 1 payment
  9. Empagliflozin and Heart failure (HFrEF) $2,394 4 payments
  10. STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis $1,119 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record